The invention provides an ophthalmic, otic or nasal pharmaceutical composition, comprising
levofloxacin or the pharmaceutical acceptable salts thereof and loteprednol etabonate, wherein the weight ratio of loteprednol etabonate to
levofloxacin is 1:0.2-5. The use of ophthalmic, otic or nasal pharmaceutical composition of the invention in preparation of the medication for treatment of conjunctivitis,
keratitis,
blepharitis, dacrycystitis, hordeolum,
corneal ulcer and ocular infection accompanied with ophthalmitis and even
inflammation of the surrounding tissues, to prevent increase of bacterial
infection risks and the
tissue inflammation of the infected area after the ophthalmic surgeries or ocular injuries, to treat or alleviate the bacterial infection in combination with the
tissue inflammation of the infected area, or to treat tympanitis,
otitis externa and infective rhinitis.